Stay updated on Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2; no visible changes to study content or layout are evident in the screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check23 days agoChange DetectedPublications notes were updated to include Revision: v3.3.1 and clarify that publications are provided voluntarily by the person entering information; the previous wording referencing 'the study results' and the older Revision: v3.2.0 were removed.SummaryDifference0.1%

- Check30 days agoChange DetectedThe notice about government funding/status at the top of the page has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check44 days agoChange DetectedThe PEMDAC study (NCT02697630) is now displayed as Completed with updated dates and reference to study results on the Study Details page.SummaryDifference0.5%

- Check73 days agoChange Detected- Added a government funding lapse notice and operating status guidance, and a link to official status pages. - Updated software version from v3.1.0 to v3.2.0.SummaryDifference5%

- Check80 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0 with no other content changes provided.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page.